威高股份：中期報告2024.pdf

1、1概要山東威高集團醫用高分子製品股份有限公司（本公司）及其附屬公司（本集團）截至二零二四年六月三十日止六個月（期間），未經審核之收入約人民幣6,635,688,000元（二零二三年同期：約人民幣6,897,700,000元），較去年同期下跌約3.8%，未經審核之本公司擁有人應佔純利約人民幣1,107,549,000元（二零二三年同期：約人民幣1,197,767,000元），較去年同期下跌約7.5%。董事會（董事會）建議派發截至二零二四年六月三十日止六個月之中期股息每股人民幣0.0919元（二零二三年同期：每股人民幣0.0734元）。該建議須經本公司股東（股東）在即將舉行的股東特別大會上批准後，

2、方可作實。SUMMARYFor the six months ended 30 June 2024(the“Period”),the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited(the“Company”)and its subsidiaries(the“Group”)was approximately RMB6,635,688,000(same period in 2023:approximately RMB6,897,700,000),representing a decrease of

3、 approximately 3.8%as compared with the same period last year,the unaudited net profit attributable to the owners of the Company was approximately RMB1,107,549,000(same period in 2023:approximately RMB1,197,767,000),representing a decrease of approximately 7.5%as compared with the same period last y

4、ear.The board of directors(the“Board”)proposed the distribution of an interim dividend for the six months ended 30 June 2024 of RMB0.0919 per share(same period in 2023:RMB0.0734 per share).The proposal is subject to the approval of shareholders of the Company(the“Shareholders”)at the forthcoming ext

5、raordinary general meeting.SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITEDINTERIM REPORT 2024山東威高集團醫用高分子製品股份有限公司2024 中期報告 2UNAUDITED CONDENSED CONSOLIDATED INTERIM RESULTSThe Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended

6、 30 June 2024,together with the unaudited comparative figures for the same period in 2023 as follows:UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEUnaudited未經審核For the six months ended 30 June截至六月三十日止六個月20242023二零二四年二零二三年NotesRMB000RMB000附註人民幣千元人民幣千元Revenue收入36,635,6886,897,700Co